Abstract
A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed approximately 20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenomatous Polyposis Coli / prevention & control*
-
Aminoquinolines
-
Aniline Compounds
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Drug Therapy, Combination
-
Enzyme Inhibitors / therapeutic use
-
ErbB Receptors / antagonists & inhibitors
-
Mice
-
Mice, Mutant Strains
-
Organic Chemicals*
-
Quinazolines / therapeutic use
-
Sulindac / therapeutic use*
Substances
-
Aminoquinolines
-
Aniline Compounds
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Organic Chemicals
-
Quinazolines
-
Sulindac
-
CL 387785
-
ErbB Receptors
-
EKB 569